Huons Global subsidiary Huons Biopharma has shipped the first batch of the botulinum toxin "Hutox" to target the Chinese market.
Huons Biopharma said on the 16th that it signed a botulinum toxin supply contract with the 100% distribution subsidiary of its Chinese partner IMeik Technology and has shipped the first batch.
Hutox is a cosmetic and therapeutic drug with botulinum toxin (Clostridium botulinum toxin type A) as the main ingredient. It is mainly used to improve glabellar lines and crow's feet.
IMeik secured exclusive import and distribution rights for Hutox in China (including Macao and Hong Kong) from Huons Biopharma in 2022 and has been carrying out local development procedures. As a result, on Jan. 1, the National Medical Products Administration (NMPA) granted marketing authorization for the 100-unit product "Hutox (Hutox®, domestic product name Liztox·LIZTOX®)."
After quality inspection by Chinese health authorities, the products shipped this time are expected to begin local distribution as early as the second half of this year. Once Hutox goes into full-scale sales, it will become the seventh botulinum toxin commercialized in China and the second from a Korean company.
A Huons Biopharma official said, "With this first shipment as a starting point, we will strengthen cooperation with IMeik for distribution and marketing in China," and added, "Hutox is expected to contribute to expanding global sales starting this year."